Financing - March 13, 2019
Herantis Pharma raises 5.8 million EUR
The Finnish biotech company has announced a positive outcome of a directed share issue, gaining additional support from long-term strategic institutional investors. The share capital will not be increased. Instead, the entire subscription price of EUR 5,782,306.40 will be recorded in the invested unrestricted equity reserve of the company. As a result of the share […]
Financing - March 11, 2019
NeuroVive raises 28.2 million SEK
The company has successfully conducted a directed new issue of shares, which has raised proceeds to NeuroVive of SEK 28.2 million before issue costs. These proceeds will be used primarily to accelerate clinical development activities, states the company in their press release. The investors are reputable Swedish and international investors led by Nyenburgh Investment Partners, […]
Biotech Business - February 26, 2019
FIT Biotech has applied for bankruptcy
The Board of Directors of the Finnish biotech company FIT Biotech has decided to file an application for bankruptcy, reports Huvudstadsbladet. The reason behind the decision is that a financing contract has been terminated. Despite the fact that one financing agreement is still effective, the investment company Alpha Blue Ocean has not paid the agreed […]
Financing - February 18, 2019
Vaccibody secures NOK 230 million
The company announces that a Private Placement has been successfully placed, raising gross proceeds of NOK 230 million by allocating 5,750,000 shares at a subscription price of NOK 40.00 per Offer Share. The Private Placement received strong interest from existing shareholders and new investors. The net proceeds from the Private Placement will i.a. be used […]
Financing - February 3, 2019
Elypta awarded 2.35 million EUR by EU’s Horizon 2020 program
Swedish Elypta announced last week that it is one of the winners in the EU program Horizon 2020 SME instrument phase 2 and has been awarded 2.35 million EUR. The grant will fund a multicenter trial for diagnoses of renal cell carcinoma (RCC), aimed at validating the company’s metabolism-based liquid biopsy platform for early detection […]
Financing - January 22, 2019
MinervaX announces investment of EUR 4.4 million
The Danish biotech company has been awarded an investment of 3.6 mEUR from the Novo Holdings REPAIR Impact Fund for development of therapies to combat antimicrobial resistance (AMR). An additional investment of 0.8 mEUR was obtained from SunStone Capital. The funding will be used to help finalize Phase I development of the company’s protein-only GBS […]
